新辅助化疗在局部晚期宫颈癌中的应用

Neoadjuvant chemotherapy in management of locally advanced cervical cancer

宫颈癌是世界范围内女性第2位常见恶性肿瘤。文献报道,新辅助化疗(NACT)可缩小局部肿瘤大小,消除肿瘤微转移灶,降低宫颈癌国际妇产科联盟(FIGO)临床分期,以增加手术可行性,并且NACT联合手术治疗,较既往的放化疗治疗,可降低治疗不良反应发生率。因此,NACT应用于局部晚期宫颈癌(LACC)治疗,成为国内外研究热点。笔者拟就NACT应用于LACC的地位、安全性、有效性及其存在的争议等进行阐述。

Cervical cancer is the second most common cancer in women in the world. Several studies have showed that the neoadjuvant chemotherapy（NACT） is effective in reducing the locally tumor size, eliminating the micrometastasis, and decreasing the Federation International of Gynecology and Obstetrics （FIGO） clinical stage of cervical cancer to improving operability. Furthermore, the combination of NACT followed by surgery is associated with fewer adverse reactions than previous chemoradiation therapy. Therefore, NACT applied in treatment of locally advanced cervical cancer （LACC） is currently being the research hotspots. This review provide a comprehensive summary of the role, safety, efficacy and controversy of NACT in the treatment of LACC.